Companies SAB Biotherapeutics, Inc.
SAB Biotherapeutics (SABS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me SAB Biotherapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $565,798FY2023
- $2,582,790FY2024
- $9,434,622FY2025
CEO total pay was $9,434,622 in fiscal 2025, up from $2,582,790 in fiscal 2024.
FY2025: salary $525,000 · option awards $8,588,160
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Samuel Reich | $525,000 | — | — | $8,588,160 | $315,000 | — | $6,462 | $9,434,622 |
| Chief Executive Officer | ||||||||
| Eddie Sullivan | 485,000 | — | — | 5,367,600 | 247,500 | — | 14,000 | 6,114,100 |
| President | ||||||||
| Alexandra Kropotova | 540,750 | — | — | 4,294,080 | 277,449 | — | 14,000 | 5,126,279 |
| EVP, Chief Medical Officer | ||||||||
| Lucy To | 475,000 | — | — | 2,147,040 | 207,572 | — | 1,462 | 2,831,074 |
| EVP, Chief Financial Officer | ||||||||
| Christoph Bausch | 425,000 | — | — | 1,073,520 | 170,000 | — | 14,000 | 1,682,520 |
| EVP, Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Samuel Reich | $9,434,622 | $2,582,790 | $565,798 | ↑ +6,851,832 |
| Eddie Sullivan | 6,114,100 | 1,597,155 | 605,157 | ↑ +4,516,945 |
| Alexandra Kropotova | 5,126,279 | 1,344,200 | 921,575 | ↑ +3,782,079 |
| Lucy To | 2,831,074 | 404,431 | — | ↑ +2,426,643 |
| Christoph Bausch | 1,682,520 | 1,196,747 | 549,323 | ↑ +485,773 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company is an emerging growth company that has elected to comply with scaled disclosure requirements and is not required to include a Compensation Discussion and Analysis section.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Alexandra Kropotova | Option | 344 | 7.11 | — |
| Eddie Sullivan | Option | 657 | 7.11 | — |
| Eddie Sullivan | Option | 2,872 | 2.9 | — |
| Alexandra Kropotova | RSU | 3,750 | — | 14,025 |
| Christoph Bausch | Option | 5,154 | 7.11 | — |
| Alexandra Kropotova | RSU | 8,588 | — | 32,119 |
| Christoph Bausch | Option | 8,594 | 5.35 | — |
| Samuel Reich | Option | 9,844 | 7.11 | — |
| Samuel Reich | Option | 16,407 | 5.35 | — |
| Eddie Sullivan | Option | 16,407 | 5.35 | — |
| Christoph Bausch | Option | 18,890 | 2.9 | — |
| Samuel Reich | Option | 23,057 | 2.9 | — |
| Alexandra Kropotova | Option | 75,834 | 5.17 | — |
| Christoph Bausch | Option | 75,834 | 5.17 | — |
| Lucy To | Option | 83,334 | 2.35 | — |
| Eddie Sullivan | Option | 102,917 | 5.17 | — |
| Samuel Reich | Option | 235,084 | 5.17 | — |
| Christoph Bausch | Option | 600,000 | 2.17 | — |
| Lucy To | Option | 1,200,000 | 2.17 | — |
| Alexandra Kropotova | Option | 2,400,000 | 2.17 | — |
| Eddie Sullivan | Option | 3,000,000 | 2.17 | — |
| Samuel Reich | Option | 4,800,000 | 2.17 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Erick LuceraIndependent · Audit (Chair) · Compensation | $43,000 | $0 | $453,255 | — | $0 | $496,255 |
| Katie ElliasIndependent · Audit · Compensation (Chair) | 37,000 | 0 | 453,255 | — | 0 | 490,255 |
| David Link, MBAIndependent · Nominating (Chair) | 36,000 | 0 | 453,255 | — | 0 | 489,255 |
| William Polvino, MDIndependent · Audit | 36,000 | 0 | 453,255 | — | 0 | 489,255 |
| Scott GibersonIndependent · Compensation · Nominating | 35,250 | 0 | 453,255 | — | 0 | 488,505 |
| Jay S. Skyler, MDIndependent · Nominating | 34,000 | 0 | 453,255 | — | 0 | 487,255 |
| Jeffrey G. SpragensIndependent · Departed during FY | 27,000 | 0 | 0 | — | — | 27,000 |
| David Zaccardelli, Pharm.DIndependent · Board Chair · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Samuel J. ReichEmployee director | — | — | — | — | — | 0 |
| Eddie J. Sullivan, PhDEmployee director | — | — | — | — | — | 0 |
| Rita Jain, MDIndependent | 0 | 0 | 0 | — | 0 | 0 |
| Andrew MoinIndependent · Nominating | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $150,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $248,250 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $248,250 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names SAB Biotherapeutics as a peer
Companies that benchmark against SABS
1 company names SABS as a compensation peer
- KYNTRA BIO, INC.FGENFY2025
Each company listed discloses SABS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SABS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | SAB Biotherapeutics, Inc. | 2025 | Samuel Reich | $525,000 | — | $8,588,160 | $315,000 | $9,434,622 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | — | — | — | — | — |
| 2025 | 2025-09-26 | — | — | — | — | — |
| 2024 | 2024-06-27 | — | — | — | — | — |
| 2023 | 2023-11-22 | — | — | — | — | — |
| 2022 | 2022-07-06 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-18 | —a |
| 2025 | 2025-09-26 | —b |
| 2024 | 2024-06-27 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Alexandra Kropotova | Chief Medical Officer | 2026-06-25 | D | 988 | — | — | Common | Form 4 ↗ |
| Alexandra Kropotova | Chief Medical Officer | 2026-09-17 | D | 473 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (25 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Samuel Reich. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · page 25. As printed: 9,434,622. View filing ↗
- Section 01, Eddie Sullivan. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 6,114,100. View filing ↗
- Section 01, Alexandra Kropotova. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 5,126,279. View filing ↗
- Section 01, Lucy To. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 2,831,074. View filing ↗
- Section 01, Christoph Bausch. DEF 14A, filed 2026-04-30. Section “Executive Compensation”. As printed: 1,682,520. View filing ↗
- Section 08, Erick Lucera. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 496,255. View filing ↗
- Section 08, Katie Ellias. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 490,255. View filing ↗
- Section 08, David Link, MBA. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 489,255. View filing ↗
- Section 08, William Polvino, MD. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 489,255. View filing ↗
- Section 08, Scott Giberson. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 488,505. View filing ↗
- Section 08, Jay S. Skyler, MD. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 487,255. View filing ↗
- Section 08, Jeffrey G. Spragens. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 27,000. View filing ↗
- Section 08, David Zaccardelli, Pharm.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Samuel J. Reich. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Eddie J. Sullivan, PhD. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Rita Jain, MD. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Andrew Moin. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Alexandra Kropotova 2026-06-25. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alexandra Kropotova 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-18. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-09-26. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-27. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 248,250 + equity 0 + all other 0 = 248,250, summed across the director compensation table rows.
- SAB Biotherapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in SAB Biotherapeutics, Inc.'s own proxy. As printed: 9,434,622. View filing ↗